Northwire Canada EditionTuesday, July 14, 2026
Northwire
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
M&A / Property

Ventripoint Partners with First Light Health to Bring AI-Powered Cardiac Diagnostics to Indigenous and Remote Communities

VPT · Price

Executive Summary

  • Ventripoint Diagnostics announced a partnership with First Light Health to deploy a hub‑and‑spoke cardiac imaging model for Indigenous and remote communities across Canada.
  • The collaboration leverages Ventripoint’s AI‑assisted VMS+™ system, enabling on‑site 2D echocardiograms to be converted into MRI‑level 3‑D volumetric images that are transmitted digitally to central specialist hubs.
  • The initiative aims to reduce travel, cost, and wait times for cardiac diagnostics, with plans for national rollout and future international expansion.

Key Details

  • Partnership Scope: Central hub located in Vancouver (operated by First Light Health) supporting remote sites in British Columbia, Yukon, Alberta, Manitoba, and New Brunswick.
  • Technology Used: Ventripoint’s VMS+™ system – AI‑driven Knowledge Based Reconstruction that delivers MRI‑grade cardiac measurements from standard 2D ultrasound scans.
  • Target Population: Indigenous peoples and other underserved patients in remote communities who face barriers to specialist cardiac care.
  • Operational Model: “Hub‑and‑spoke” – local providers capture and enhance scans, transmit them digitally to hub specialists for rapid interpretation and consultation.
  • Geographic Expansion: Current rollout across multiple Canadian provinces with intent to expand internationally where VMS+™ is approved (U.S., Europe, other markets).
  • Clinical Impact: Expected to shorten diagnostic timelines, lower costs, and improve early detection of cardiovascular disease, congenital heart defects, heart failure, pulmonary hypertension, and chemotherapy‑related cardiac complications.
  • Leadership Comments:
  • Hugh MacNaught, CEO of Ventripoint – emphasized the need for scalable, equitable heart care and potential global deployment (“from the Arctic to the Amazon”).
  • Dr. Ripenjot Rai, Medical Director, First Light Health – highlighted the partnership’s role in reconciliation and culturally safe, trauma‑informed care.

Notable Quotes

  • “Cardiovascular disease doesn’t respect geography – but too often, access to cardiac care does.” – Hugh MacNaught, CEO, Ventripoint Diagnostics Ltd.
  • “Collaborations like this help ensure patients in Indigenous and remote communities receive timely, high‑quality care while remaining connected to their communities.” – Dr. Ripenjot Rai, Medical Director, First Light Health.
Read the original news release →

More from VentriPoint Diagnostics Ltd.